Float Short %

13.54

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

-0.1

EPS Last/This Y

-3

EPS This/Next Y

-0.07

Price

23.44

Target Price

47.93

Analyst Recom

1.88

Performance Q

-12.18

Relative Volume

0.78

Beta

1.92

Ticker: BEAM

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	BEAM	26.83	0.38	0.67	17211
2024-12-20	BEAM	29.02	0.33	0.22	16643
2024-12-23	BEAM	28.7	0.22	0.18	8202
2024-12-24	BEAM	28.81	0.22	0.02	8319
2024-12-26	BEAM	28.7	0.22	0.06	8379
2024-12-27	BEAM	26.58	0.21	2.61	8470
2024-12-30	BEAM	25.3	0.24	0.62	8630
2024-12-31	BEAM	24.81	0.24	0.92	8698
2025-01-02	BEAM	24.68	0.25	0.18	8818
2025-01-03	BEAM	25.36	0.26	1.37	8923
2025-01-06	BEAM	26.18	0.27	0.06	9056
2025-01-07	BEAM	27.08	0.28	0.70	8951
2025-01-08	BEAM	26.72	0.28	0.10	9155
2025-01-09	BEAM	26.8	0.28	0.10	9155
2025-01-10	BEAM	26.37	0.27	0.16	9397
2025-01-13	BEAM	25.59	0.28	1.31	9410
2025-01-14	BEAM	23.41	0.28	0.22	9447
2025-01-15	BEAM	23.4	0.28	0.04	9588
2025-01-16	BEAM	23.41	0.28	0.25	9675
2025-01-17	BEAM	23.44	0.28	0.12	9770
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	BEAM	26.83	-173.8	-	-4.72
2024-12-20	BEAM	29.03	-173.8	-	-4.72
2024-12-23	BEAM	28.70	-173.8	-	-4.72
2024-12-24	BEAM	28.81	-173.8	-	-4.72
2024-12-26	BEAM	28.70	-173.8	-	-4.72
2024-12-27	BEAM	26.56	-173.8	-	-4.72
2024-12-30	BEAM	25.28	-173.8	-	-4.72
2024-12-31	BEAM	24.82	-173.8	-	-4.72
2025-01-02	BEAM	24.68	-173.8	-	-4.72
2025-01-03	BEAM	25.37	-173.8	-	-4.72
2025-01-06	BEAM	26.35	-173.8	-	-4.72
2025-01-07	BEAM	27.05	-173.8	-	-4.72
2025-01-08	BEAM	26.80	-173.8	-	-4.72
2025-01-09	BEAM	26.80	-173.8	-	-4.72
2025-01-10	BEAM	26.36	-173.8	-	-4.72
2025-01-13	BEAM	25.56	-173.8	-	-4.72
2025-01-14	BEAM	23.30	-173.8	-	-4.72
2025-01-15	BEAM	23.41	-173.8	-	-4.72
2025-01-16	BEAM	23.40	-173.8	-	-4.72
2025-01-17	BEAM	23.44	-173.8	-	-4.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	BEAM	-2.17	5.98	14.69
2024-12-20	BEAM	-2.17	5.98	14.69
2024-12-23	BEAM	-2.01	5.98	14.69
2024-12-24	BEAM	-2.01	5.98	14.70
2024-12-26	BEAM	-2.15	5.98	13.84
2024-12-27	BEAM	-2.16	5.98	13.84
2024-12-30	BEAM	-1.72	5.72	13.84
2024-12-31	BEAM	-1.72	5.72	13.84
2025-01-02	BEAM	-1.62	5.72	13.84
2025-01-03	BEAM	-1.59	5.72	13.84
2025-01-06	BEAM	-1.54	6.20	13.84
2025-01-07	BEAM	-1.56	6.20	13.84
2025-01-08	BEAM	-1.60	6.20	13.84
2025-01-09	BEAM	-1.59	6.20	13.86
2025-01-10	BEAM	-1.59	6.20	13.86
2025-01-13	BEAM	-1.59	5.97	13.54
2025-01-14	BEAM	-1.59	5.97	13.54
2025-01-15	BEAM	-1.59	5.97	13.54
2025-01-16	BEAM	-1.59	5.97	13.54
2025-01-17	BEAM	-1.59	5.97	13.54
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-1.28

Avg. EPS Est. Next Quarter

-1.27

Insider Transactions

-1.59

Institutional Transactions

5.97

Beta

1.92

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

83.1

Max Drawdown 5-Year %

Target Price

47.93

P/E

Forward P/E

PEG

P/S

5.55

P/B

2.45

P/Free Cash Flow

EPS

-1.76

Average EPS Est. Cur. Y

-4.72

EPS Next Y. (Est.)

-4.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-41.07

Relative Volume

0.78

Return on Equity vs Sector %

-37.2

Return on Equity vs Industry %

-24.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Beam Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 472

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

stock quote shares BEAM – Beam Therapeutics Inc. Stock Price stock today

news today BEAM – Beam Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BEAM – Beam Therapeutics Inc. yahoo finance google finance

stock history BEAM – Beam Therapeutics Inc. invest stock market

stock prices BEAM premarket after hours

ticker BEAM fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BEAM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y